专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US08436207B2 Naphthalene-based inhibitors of anti-apoptotic proteins 有权
标题翻译：基于萘的抗凋亡蛋白抑制剂
公开(公告)号：US08436207B2
公开(公告)日：2013-05-07
申请号：US13238910
申请日：2011-09-21
申请人： Maurizio Pellecchia
发明人： Maurizio Pellecchia
IPC分类号： C07C233/65 , A61K31/16
CPC分类号： G01N33/564 , C07C39/14 , C07C49/83 , C07C235/66 , C07C311/29 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07D277/64 , C07D417/10 , C12Q1/6883 , C12Q1/6886 , G01N33/57407 , G01N2800/042 , G01N2800/046 , G01N2800/065 , G01N2800/10 , G01N2800/101 , G01N2800/102 , G01N2800/104 , G01N2800/105 , G01N2800/122 , G01N2800/127 , G01N2800/202 , G01N2800/205 , G01N2800/222 , G01N2800/226 , G01N2800/24 , G01N2800/28 , G01N2800/2821 , G01N2800/285 , G01N2800/32 , G01N2800/325 , G01N2800/328 , G01N2800/347 , G01N2800/52
摘要： Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: wherein each R is independently H, C(O)X, C(O)NHX, NH(CO)X, SO2NHX, or NHSO2X, wherein X is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, heterocycle, or substituted heterocycle. Compounds of group A may be used for treating various diseases or disorders, such as cancer.
摘要翻译：公开了使用果糖酚及其衍生物治疗炎症的方法。另外，提供了一组具有结构A的化合物或其药学上可接受的盐，水合物，N-氧化物或溶剂合物：其中每个R独立地为H，C（O）X，C（O）NHX， NH（CO）X，SO2NHX或NHSO2X，其中X是氢，烷基，取代的烷基，芳基，取代的芳基，烷基芳基，取代的烷基芳基，杂环或取代的杂环。 A组的化合物可用于治疗各种疾病或病症，例如癌症。

12. 发明申请

US20130052206A1 Prognostic Marker For Cryoglobulinemic Vasculitis And B Cell Malignancies In HCV Infected Patients 审中-公开
标题翻译： HCV感染患者的慢性淋巴细胞性血管炎和B细胞恶性肿瘤的预后标记
公开(公告)号：US20130052206A1
公开(公告)日：2013-02-28
申请号：US13581759
申请日：2011-02-28
申请人： Vincent Agnello
发明人： Vincent Agnello
IPC分类号： C12Q1/70 , A61P13/12 , A61P17/00 , A61K39/395
CPC分类号： C12Q1/6886 , C07K16/28 , G01N33/57426 , G01N33/5767 , G01N33/686 , G01N2800/328 , G01N2800/52
摘要： The invention provides methods and compositions for early diagnosis and treatment of a disease associated with a specific antibody by employing the detection of a cross-idiotypic epitope on the specific antibody to detect the cells that produce the antibody before the development of clinical symptoms of the disease.
摘要翻译：本发明提供用于早期诊断和治疗与特异性抗体相关疾病的方法和组合物，其通过使用特异性抗体上的交叉独特型表位的检测来检测在发展该疾病的临床症状之前产生抗体的细胞。

13. 发明申请

US20120003228A1 METHODS FOR PREDICTING AUTOIMMUNE DISEASE RISK 审中-公开
标题翻译：预防自发性疾病风险的方法
公开(公告)号：US20120003228A1
公开(公告)日：2012-01-05
申请号：US13145052
申请日：2010-01-20
申请人： Ken Smith , Paul Lyons , Eoin McKinney
发明人： Ken Smith , Paul Lyons , Eoin McKinney
IPC分类号： G01N33/566 , C12Q1/68 , C40B30/04 , A61K31/662 , A61K39/395 , A61K31/56 , A61K31/52 , A61K31/5377 , A61P37/00 , A61P19/04 , A61P29/00 , A61P7/00 , A61P25/00 , A61P1/00 , H01J49/00 , C40B30/00
CPC分类号： G01N33/564 , C12Q1/6883 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158 , G01N2333/705 , G01N2333/7055 , G01N2333/916 , G01N2800/042 , G01N2800/102 , G01N2800/104 , G01N2800/245 , G01N2800/285 , G01N2800/328 , G01N2800/50 , G01N2800/52
摘要： The invention relates to means and methods for determining whether a subject is at high or low risk of autoimmune disease progression by determining the CD8 or CD4 cell subtype of the subject. Autoimmune diseases of particular interest include vasculitis, systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. The invention also relates to means and methods for determining the CD8 or CD4 cell subtype of a subject, e.g. for predicting responses to infection, vaccination and/or transplantation.
摘要翻译：本发明涉及通过确定受试者的CD8或CD4细胞亚型来确定受试者是否处于高度或低风险的自身免疫性疾病进展的手段和方法。特别有意义的自身免疫性疾病包括血管炎，系统性红斑狼疮（SLE），类风湿性关节炎，多发性硬化和炎症性肠病。本发明还涉及用于确定受试者的CD8或CD4细胞亚型的方法和方法，例如，用于预测感染，疫苗接种和/或移植的反应。

14. 发明授权

US08039668B2 Naphthalene-based inhibitors of anti-apoptotic proteins 有权
标题翻译：基于萘的抗凋亡蛋白抑制剂
公开(公告)号：US08039668B2
公开(公告)日：2011-10-18
申请号：US12760380
申请日：2010-04-14
申请人： Maurizio Pellecchia
发明人： Maurizio Pellecchia
IPC分类号： C07C233/05 , A61K31/65
CPC分类号： G01N33/564 , C07C39/14 , C07C49/83 , C07C235/66 , C07C311/29 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07D277/64 , C07D417/10 , C12Q1/6883 , C12Q1/6886 , G01N33/57407 , G01N2800/042 , G01N2800/046 , G01N2800/065 , G01N2800/10 , G01N2800/101 , G01N2800/102 , G01N2800/104 , G01N2800/105 , G01N2800/122 , G01N2800/127 , G01N2800/202 , G01N2800/205 , G01N2800/222 , G01N2800/226 , G01N2800/24 , G01N2800/28 , G01N2800/2821 , G01N2800/285 , G01N2800/32 , G01N2800/325 , G01N2800/328 , G01N2800/347 , G01N2800/52
摘要： Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: wherein each R is independently H, C(O)X, C(O)NHX, NH(CO)X, SO2NHX, or NHSO2X, wherein X is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, heterocycle, or substituted heterocycle. Compounds of group A may be used for treating various diseases or disorders, such as cancer.
摘要翻译：公开了使用果糖酚及其衍生物治疗炎症的方法。另外，提供了一组具有结构A的化合物或其药学上可接受的盐，水合物，N-氧化物或溶剂合物：其中每个R独立地为H，C（O）X，C（O）NHX， NH（CO）X，SO2NHX或NHSO2X，其中X是氢，烷基，取代的烷基，芳基，取代的芳基，烷基芳基，取代的烷基芳基，杂环或取代的杂环。 A组的化合物可用于治疗各种疾病或病症，例如癌症。

15. 发明申请

US20100267781A1 NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS 有权
标题翻译：基于萘基的抗微生物蛋白抑制剂
公开(公告)号：US20100267781A1
公开(公告)日：2010-10-21
申请号：US12760380
申请日：2010-04-14
申请人： Maurizio Pellechia
发明人： Maurizio Pellechia
IPC分类号： A61K31/05 , C07C49/83 , A61K31/12 , C07D417/10 , A61K31/428 , C07C39/14 , C07C43/20 , A61K31/09 , C07C47/575 , A61K31/11 , C07C63/36 , A61K31/194 , C07C237/48 , A61K31/166 , A61K31/353 , A61P35/00 , A61P29/00 , A61P25/28 , A61P37/06 , A61P3/10 , C12Q1/02 , C12Q1/68 , C12N5/02
CPC分类号： G01N33/564 , C07C39/14 , C07C49/83 , C07C235/66 , C07C311/29 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07D277/64 , C07D417/10 , C12Q1/6883 , C12Q1/6886 , G01N33/57407 , G01N2800/042 , G01N2800/046 , G01N2800/065 , G01N2800/10 , G01N2800/101 , G01N2800/102 , G01N2800/104 , G01N2800/105 , G01N2800/122 , G01N2800/127 , G01N2800/202 , G01N2800/205 , G01N2800/222 , G01N2800/226 , G01N2800/24 , G01N2800/28 , G01N2800/2821 , G01N2800/285 , G01N2800/32 , G01N2800/325 , G01N2800/328 , G01N2800/347 , G01N2800/52
摘要： Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: wherein each R is independently H, C(O)X, C(O)NHX, NH(CO)X, SO2NHX, or NHSO2X, wherein X is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, heterocycle, or substituted heterocycle. Compounds of group A may be used for treating various diseases or disorders, such as cancer.
摘要翻译：公开了使用果糖酚及其衍生物治疗炎症的方法。另外，提供了一组具有结构A的化合物或其药学上可接受的盐，水合物，N-氧化物或溶剂合物：其中每个R独立地为H，C（O）X，C（O）NHX， NH（CO）X，SO2NHX或NHSO2X，其中X是氢，烷基，取代的烷基，芳基，取代的芳基，烷基芳基，取代的烷基芳基，杂环或取代的杂环。 A组的化合物可用于治疗各种疾病或病症，例如癌症。

16. 发明申请

US20100221186A1 BIOMARKERS FOR CARDIOVASCULAR SIDE-EFFECTS INDUCED BY COX-2 INHIBITORY COMPOUNDS 审中-公开
标题翻译：由COX-2抑制化合物引起的心脏血管副作用的生物标志物
公开(公告)号：US20100221186A1
公开(公告)日：2010-09-02
申请号：US12293652
申请日：2006-03-10
申请人： Hueseyin Firat , Julie Boisclair , Olivier Grenet , Perentes Elias , Martin M. Schumacher
发明人： Hueseyin Firat , Julie Boisclair , Olivier Grenet , Perentes Elias , Martin M. Schumacher
IPC分类号： A61K49/00 , C07D231/12 , A61K39/00 , G01N33/53 , C07C63/331 , C07D307/46 , A61P37/04
CPC分类号： C12Q1/6883 , A61K31/00 , C12Q2600/106 , C12Q2600/142 , C12Q2600/158 , G01N33/68 , G01N2800/328
摘要： Cardiovascular tissue mRNA expression profiles in monkeys treated with coxibs was analyzed. Genomic data indicated that the animals showing vasculitis exhibit a specific mRNA expression pattern. The pattern includes gene expression changes involved in blood and endothelial cell (EC) activation, interaction of blood cells with EC, activation of INFγ pathway, and release of pro-inflammatory cytokines and chemo-attractants. These results provide direct evidence of minimal vasculitis together with corresponding genomic signature and peripheral biomarkers for minimal vasculatis. These results also suggest that treatment might triggers/aggravate a clinically latent cardiovascular disorder in the context of an endothelium tropic viral infection and/or an autoimmune vascular disorder. The histopathological examination revealed marginal vascular changes consistent with the genomic findings. Measurement of soluble proteins present in serum and plasma using a multiplex assay were in line with the genomic results, showing the increased level of INFγ inducible proteins, increased expression of CXCL10 chemokine was confirmed by an ELISA both in serum and plasma. Use of these peripheral biomarkers allows a safe usage of cox-2 inhibitory compounds in clinics and selection of cox-2 inhibitory follow-up compounds with no cardiovascular toxicity. These data together with biochemical and histopathological findings suggest that the specific cox2 inhibitor may exaggerate host immune response during some specific viral infections with endothelial tropism, or subjacent vascular autoimmune disorders.
摘要翻译：分析用coxibs处理的猴子的心血管组织mRNA表达谱。基因组数据表明，显示血管炎的动物表现出特异的mRNA表达模式。该模式包括参与血液和内皮细胞（EC）激活，血细胞与EC的相互作用，INFγ通路的激活和促炎细胞因子和化学引诱物的释放的基因表达变化。这些结果提供了最小血管炎的直接证据，以及相应的基因组特征和用于最小血管平滑肌的外周生物标志物。这些结果还表明治疗可能在内皮热带病毒感染和/或自身免疫性血管疾病的背景下触发/加重临床上潜在的心血管疾病。组织病理学检查发现边缘血管变化与基因组结果一致。使用多重测定法测定血清和血浆中的可溶性蛋白质与基因组结果一致，显示INFγ诱导型蛋白水平升高，CXCL10趋化因子表达增加通过血清和血浆中的ELISA证实。使用这些外周生物标志物可以安全使用cox-2抑制性化合物在临床和选择没有心血管毒性的cox-2抑制性后续化合物。这些数据以及生物化学和组织病理学研究结果表明，特定的cox2抑制剂可能在具有内皮向性或下部血管自身免疫疾病的特定病毒感染期间夸大宿主免疫应答。

17. 发明申请

US20030175822A1 Opiate, cannabinoid, and estrogen receptors 审中-公开
标题翻译：鸦片，大麻素和雌激素受体
公开(公告)号：US20030175822A1
公开(公告)日：2003-09-18
申请号：US10338306
申请日：2003-01-08
发明人： George B. Stefano , Caterina Fimiani
IPC分类号： G01N033/53 , G01N033/567 , C07H021/04 , C12P021/02 , C12N005/06 , C07K014/72 , C07K014/705 , A61K031/137
CPC分类号： G01N33/5011 , A61K31/00 , A61K31/138 , A61K45/06 , A61K47/6425 , C07K14/705 , C07K14/721 , G01N33/5008 , G01N33/502 , G01N33/5064 , G01N33/6872 , G01N33/948 , G01N33/9486 , G01N2333/723 , G01N2800/102 , G01N2800/104 , G01N2800/328
摘要： The present invention relates generally to mu3 opiate receptors, cannabinoid receptors, and estrogen surface receptors (ESRs). Specifically, the invention provides methods and materials for identifying mu3 opiate receptor agonists and antagonists, cannabinoid receptor agonists and antagonists, and ESR agonists and antagonists. In addition, the invention provides an isolated nucleic acid molecule that encodes a mu3 opioid receptor, a host cell containing an isolated nucleic acid molecule that encodes a mu3 opioid receptor, and an isolated mu3 opioid receptor polypeptide. Further, the invention provides methods and materials for treating cancers, inflammatory conditions, sepsis conditions, viral infections, and cardiovascular diseases.
摘要翻译：本发明一般涉及mu3鸦片类受体，大麻素受体和雌激素表面受体（ESR）。具体地，本发明提供了用于鉴定mu3鸦片剂受体激动剂和拮抗剂，大麻素受体激动剂和拮抗剂以及ESR激动剂和拮抗剂的方法和材料。此外，本发明提供编码mu3阿片受体的分离的核酸分子，含有编码mu3阿片受体的分离的核酸分子的宿主细胞和分离的mu3阿片受体多肽。此外，本发明提供了治疗癌症，炎性病症，败血病病症，病毒感染和心血管疾病的方法和材料。

18. 发明申请

US20180207238A1 COMPOSITIONS AND METHODS FOR REGULATING LEUKOCYTE ADHESION 审中-公开
公开(公告)号：US20180207238A1
公开(公告)日：2018-07-26
申请号：US15746484
申请日：2016-07-29
申请人： University of Virginia Patent Foundation
发明人： Brant E. Isakson
IPC分类号： A61K38/20 , A61P29/00 , A61P7/00 , A61K38/17 , G01N33/50
CPC分类号： A61K38/2013 , A61K38/1709 , A61P7/00 , A61P29/00 , C07K14/435 , C07K2319/10 , G01N33/5064 , G01N2800/328
摘要： Inflammatory cell recruitment to local sites of tissue injury and/or infection is controlled by many signaling processes influencing cell-to-cell interactions between vascular endothelial cells (EC) in post-capillary venules and circulating leukocytes. Here we report that the ATP-release channel Pannexin1 (Panx1) opens downstream of EC activation by tumor necrosis factor α (TNF α). This process involves activation of Type 1 TNF receptors, recruitment of Src Family Kinases (SFK), and SFK-dependent phosphorylation of Panx1. We report a previously unidentified role for Panx1 channels in promoting leukocyte adhesion and emigration through the venous wall during acute systemic inflammation. The present application further discloses that Panx IL2 peptide consisting of amino acid sequence KYPIVEQYLKYGRKKQRR (SEQ ID NO: 3) or 10Panx1 peptide consisting of amino acid sequence WRQAAFVDSY (SEQ ID NO: 8) are inhibitors of leukocyte adhesion.

19. 发明申请

US20170322228A1 METHOD, KIT AND TEST STRIP FOR DETECTING KAWASAKI DISEASE 审中-公开
公开(公告)号：US20170322228A1
公开(公告)日：2017-11-09
申请号：US15659815
申请日：2017-07-26
申请人： PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY
发明人： Yayoi HORIUCHI , Masaaki Mori , Hisashi Hirano , Shumpei Yokota , Yoko Saito , Mao Aketagawa
IPC分类号： G01N33/68 , G01N33/74 , G01N33/573 , G01N30/00
CPC分类号： G01N33/6893 , G01N27/447 , G01N30/00 , G01N30/90 , G01N33/558 , G01N33/573 , G01N33/68 , G01N33/74 , G01N2800/328 , G01N2800/38 , G01N2800/60
摘要： The present invention provides methods in the context of Kawasaki disease including measuring the level of at least one of lipopolysaccharide binding protein, leucine-rich alpha-2-glycoprotein, angiotensinogen and retinol binding protein 4 in a sample derived from a subject.

20. 发明申请

US20160375101A1 Methods of Using Interleukin-10 for Treating Diseases and Disorders 审中-公开
标题翻译：使用白细胞介素-10治疗疾病和疾病的方法
公开(公告)号：US20160375101A1
公开(公告)日：2016-12-29
申请号：US15110925
申请日：2015-01-09
申请人： ARMO BIOSCIENCES, INC.
发明人： Martin Oft
IPC分类号： A61K38/20 , G01N33/50 , A61K47/48 , G01N33/92 , A61K9/00 , A61K45/06
CPC分类号： A61K38/2066 , A61K9/0019 , A61K45/06 , A61K47/60 , G01N33/5088 , G01N33/92 , G01N2333/5428 , G01N2800/32 , G01N2800/323 , G01N2800/325 , G01N2800/328 , G01N2800/52
摘要： Methods for determining dosing parameters associated with subcutaneous administration of IL-10 useful for the treatment and/or prevention of a cholesterol-related disease, disorder or condition, and pharmaceutical compositions associated therewith, are provided herein. Certain embodiments are directed to means for establishing a therapeutic range of an IL-10 agent in a subject. In some embodiments, particular parameters (e.g., hematological parameters) are monitored to provide an indication of the upper limit of the therapeutic range such that any untoward adverse effects are avoided.
摘要翻译：本文提供了用于确定与用于治疗和/或预防胆固醇相关疾病，病症或病症的IL-10相关的给药参数以及与其相关的药物组合物的方法。某些实施方案涉及在受试者中建立IL-10试剂的治疗范围的手段。在一些实施方案中，监测特定参数（例如血液学参数）以提供治疗范围的上限的指示，从而避免任何不利的副作用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式